Navigation Links
Aureus Pharma Announces Renewal and Expansion of Licensing Agreement With Bristol-Myers Squibb for its AurSCOPE Knowledge Databases
Date:11/12/2007

PARIS, November 12 /PRNewswire/ -- Aureus Pharma, a leading provider of knowledge management solutions to accelerate discovery in the life sciences industry, today announced that Bristol-Myers Squibb Company (NYSE: BMY) has renewed its license to Aureus' AurSCOPE GPCR, and has also licensed Aureus' AurSCOPE Kinase and Ion Channel Knowledge databases.

Aureus Pharma's target-family-based AurSCOPE knowledge databases contain quantitative biological activity data which has been mined from the scientific literature. By understanding existing structure activity relationships, and the overall pharmacological space associated with a target/ligand, researchers can better design and prioritize experiments.

"We are very pleased that Bristol-Myers Squibb has chosen Aureus Pharma as a partner for knowledge based drug discovery," commented Jason Theodosiou, CEO of Aureus Pharma. "Bristol-Myers Squibb has been an important customer since 2002 and we regard their renewal and license extension as confirmation that our knowledge database solutions are meeting the needs of the world's leading pharmaceutical companies."

About Aureus Pharma

Aureus Pharma headquartered in Paris, France is a privately held knowledge management based solutions provider for the life sciences industry. Aureus accelerates drug discovery by providing knowledge databases which contain high quality quantitative information for both chemistry and biology. Researchers gain rapid access to knowledge for important drug target classes including GPCR, Ion Channel, Kinase as well as other critical pharma topics including ADME/Drug-Drug Interactions and the hERG Channel. The data contained in the Aureus Pharma system is of importance to aid in lead discovery and optimization as well as to build predictive models. For further information on how Aureus helps researchers turn data into discovery visit http://www.aureus-pharma.com

Media Contact:

For Aureus Pharma:

Mary E. Donlan, Ph.D

Director of Sales & Marketing

+33-1-40-18-57-59/+33-6-76-19-51-77

mary.donlan@aureus-pharma.com


'/>"/>
SOURCE Aureus Pharma
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. New ActivePure Technology Proven To Reduce Exposure to Methicillin Resistant Staphylococcus Aureus (MRSA)
2. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
3. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
6. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... Hill, N.C. (PRWEB) , ... June 27, 2016 ... ... U.S. commercial operations for Amgen, will join the faculty of the University ... serve as adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a ...
(Date:6/27/2016)... BOSTON , June 27, 2016   Ginkgo ... biology to industrial engineering, was today awarded as ... a selection of the world,s most innovative companies. ... at scale for the real world in the ... organism engineers work directly with customers including Fortune ...
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal articles ... findings are the subject of a new article on the Surviving Mesothelioma website. ... blood, lung fluid or tissue of mesothelioma patients that can help point doctors to ...
Breaking Biology Technology:
(Date:5/9/2016)... , UAE, May 9, 2016 ... when it comes to expanding freedom for high net ... Even in today,s globally connected world, there is ... conferencing system could ever duplicate sealing your deal with ... obtaining second passports by taking advantage of citizenship via ...
(Date:4/26/2016)... Research and Markets has announced ... 2016-2020"  report to their offering.  , ,     (Logo: ... analysts forecast the global multimodal biometrics market to ... period 2016-2020.  Multimodal biometrics is being ... the healthcare, BFSI, transportation, automotive, and government for ...
(Date:4/13/2016)...  IMPOWER physicians supporting Medicaid patients in ... standard in telehealth thanks to a new partnership with ... IMPOWER patients can routinely track key health measurements, such ... and, when they opt in, share them with IMPOWER ... local retail location at no cost. By leveraging this ...
Breaking Biology News(10 mins):